Multiple myeloma (MM) is still incurable - causing the death of 10,000 Americans annually. Currently, glucocorticoids and the proteasome-inhibiting drug PS-341 (Bortezomib/Velcade) rank among the most effective agents in myeloma therapy. Given that MM is a radiosensitive malignancy, radiation-based combination strategies that incorporate these cytotoxic drugs are likely to lead to effective regimens. Our overall hypothesis is that glucocorticoids and proteasome inhibitors, when combined with radiotherapy, will attenuate constitutive and radiation-induced NF?B activation, thereby inhibiting downstream IL6 synthesis, leading to the radiosensitization of myeloma cells, and inhibiting the development of drug resistance. In vitro studies will use established myeloma cell lines and patient samples co-cultured with bone marrow stromal cells. The syngeneic, orthotopic 5TGM1 myeloma model will be used for in vivo studies.
In Aim 1 we will evaluate the ability of combined dexamethasone treatment and 153-Sm-EDTMP radiotherapy to selectively enhance the therapeutic index for MM by inhibiting IL6 expression.
In Aim 2 we will explore the effects of combined dexamethasone, PS-341 and 153-Sm-EDTMP treatment with respect to enhancing the therapeutic index for MM, via inhibition of NF?B-induced IL6 expression.
In Aim 3 we will determine the effects of IL6 synthesis in the bone marrow microenvironment on the induction of cellular antioxidants, and identify the consequences with respect to the development of myeloma-cell resistance to drug treatment. The goal of this proposal is to develop radiation-based combination therapies involving cytotoxic drugs to selectively radiosensitize myeloma cells such that the myeloma-cell drug resistance in the bone marrow microenvironment is inhibited. Such studies will provide mechanistic insights into why the frontline therapies for myeloma are failing, and also establish a strong biochemical rationale for the design of a Phase I/II trial in near future with a good chance of improving the overall survival and quality of life in myeloma patients.
Multiple myeloma (MM) is a systemic malignancy that remains incurable with current therapies. Radiation- based therapies have the potential to provide significant clinical benefit in myeloma. This proposal will explore the biological effects of a novel, mechanism-based combination strategy that involves both clinically active, anti-myeloma drugs (Dexamethasone and PS-341) and radiotherapy (153-Sm-EDTMP), and that could improve remission rates and prolong the survival of myeloma patients. The results generated are likely to unravel the mechanism that leads to the development of radiation/chemotherapy-induced resistance in MM. Furthermore, this study is expected to provide a strong biochemical rationale for designing a non- myeloablative, radionuclide-based Phase I/II trial in near future that can be extended to patients who are not candidates for stem cell transplantation, or who relapse following conventional myeloma therapy.
|Salem, Kelley; McCormick, Michael L; Wendlandt, Erik et al. (2015) Copper-zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma. Redox Biol 4:23-33|
|Fletcher, Elise V M; Love-Homan, Laurie; Sobhakumari, Arya et al. (2013) EGFR inhibition induces proinflammatory cytokines via NOX4 in HNSCC. Mol Cancer Res 11:1574-84|
|Brown, Charles O; Schibler, Jeanine; Fitzgerald, Matthew P et al. (2013) Scavenger receptor class A member 3 (SCARA3) in disease progression and therapy resistance in multiple myeloma. Leuk Res 37:963-9|
|Salem, Kelley; Brown, Charles O; Schibler, Jeanine et al. (2013) Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-ÎºB activity. Exp Hematol 41:209-18|
|Jung, Jae-Joon; Tiwari, Ajit; Inamdar, Shivangi M et al. (2012) Secretion of soluble vascular endothelial growth factor receptor 1 (sVEGFR1/sFlt1) requires Arf1, Arf6, and Rab11 GTPases. PLoS One 7:e44572|
|Brown, Charles O; Salem, Kelley; Wagner, Brett A et al. (2012) Interleukin-6 counteracts therapy-induced cellular oxidative stress in multiple myeloma by up-regulating manganese superoxide dismutase. Biochem J 444:515-27|
|Goel, Apollina; Spitz, Douglas R; Weiner, George J (2012) Manipulation of cellular redox parameters for improving therapeutic responses in B-cell lymphoma and multiple myeloma. J Cell Biochem 113:419-25|
|Tiwari, Ajit; Jung, Jae-Joon; Inamdar, Shivangi M et al. (2011) Endothelial cell migration on fibronectin is regulated by syntaxin 6-mediated alpha5beta1 integrin recycling. J Biol Chem 286:36749-61|
|Manickam, Venkatraman; Tiwari, Ajit; Jung, Jae-Joon et al. (2011) Regulation of vascular endothelial growth factor receptor 2 trafficking and angiogenesis by Golgi localized t-SNARE syntaxin 6. Blood 117:1425-35|
|Bera, Soumen; Greiner, Suzanne; Choudhury, Amit et al. (2010) Dexamethasone-induced oxidative stress enhances myeloma cell radiosensitization while sparing normal bone marrow hematopoiesis. Neoplasia 12:980-92|